See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a medication used to treat a variety of conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. While Cosentyx has been shown to be effective in treating these conditions, prolonged use may carry certain risks.

One potential risk of prolonged Cosentyx use is an increased susceptibility to infections. Cosentyx works by suppressing the immune system, which can make users more vulnerable to developing infections. This risk may be higher in individuals who take Cosentyx for extended periods of time.

Another potential risk of prolonged Cosentyx use is the development of antibodies against the medication. Over time, the body may develop antibodies that reduce the effectiveness of Cosentyx, requiring higher doses or alternative treatments.

Additionally, there is limited long-term data on the safety and efficacy of Cosentyx, as it has only been on the market since 2015. Therefore, the full range of risks associated with prolonged use is not yet fully understood.

It is important for individuals taking Cosentyx to discuss the risks and benefits of prolonged use with their healthcare provider. Regular monitoring for signs of infection or decreased effectiveness may also be necessary.

Sources:

1. Cosentyx (secukinumab) [Monograph]. (2021). Retrieved from <https://www.drugs.com/cosentyx.html>
2. Secukinumab. (2021). Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK537231/>
3. Secukinumab (Cosentyx). (2021). Retrieved from <https://www.drugpatentwatch.com/secukinumab-cosentyx/>